Market Research Logo

European Pharmaceutical Market Access, Pricing & Reimbursement

European Pharmaceutical Market Access, Pricing & Reimbursement

SMi Group’s 22nd annual European Pharmaceutical Market Access, Pricing and Reimbursement conference returns to London from 10-11 October 2016. The conference is one of the most established in the world, focusing on the changes in pricing and reimbursement and market access.

As pharmaceutical global spending is predicted to increase by 29-32% by 2020*, the need for access to cheaper alternative medicines and technology is essential. The use of generics is on the rise and it's expected that by 2020, 88%* of total medicine use will be attributed to generics, over the counter, and non-original branded products.

Source: http://bit.ly/1jb3s88

This year's agenda will have a strong focus on the future of pricing and reimbursement. Other key topics include:

Updates on AMNOG and its implication on pricing and reimbursement
How biosimilars are affecting your pricing strategy
Capture on emerging markets’ regulatory framework to adapt your market access and P&R models
Orphan drugs using recent examples to highlight the impact on pricing
Cancer drug funding and budget cuts in the UK
Innovative solutions beyond the pill
Japanese and Turkish regional updates


Day 1
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Bertram Haussler, Chairman of the Board of Management, IGES Institut
9:10
OPENING ADDRESS: Current challenges in European market access, pricing and reimbursement
Alexander Natz, Director, EUCOPE
9:50
New Cancer Drug Fund (CDF) UK 2016: What have we learned from the transition period?
Smita Sealey, UK Engagement Manager, Market Access, IMS Health
10:30
Morning Coffee
11:00
AMNOG: Strengths, challenges and where next?
Bertram Haussler, Chairman of the Board of Management, IGES Institut
11:40
Value based pricing - is it affordable?
Patrick Mollon, Former Director Global Health Economics and Outcomes Research; HEOR Director, Novartis; PMHE2020
12:20
Networking Lunch
13:20
Rare diseases and orphan drugs: A market access outlook
Gordon Spencer, Regional Market Access Lead, EU & Canada , Shire
14:00
Unlocking the Value of Biosimilars for Payors, Prescribers, Patients & Industry
Adam Levysohn, Head of Global Market Access Biosimilars Business Unit, Biogen Idec
14:40
Afternoon Tea
15:10
Japan: 2016 P&R reforms
Donald Macarthur, Global Pharmaceutical Business Analyst ,
16:00
Chairman’s Closing Remarks and Close of Day One
Day 2
8:30
Registration & Coffee
9:00
Chairman's Opening Remarks
Gordon Spencer, Regional Market Access Lead, EU & Canada , Shire
9:10
OPENING ADDRESS: Biosimilars and their impact on pricing and reimbursement
Jorge Mestre-Ferrandiz, Director of Consulting, Office of Health Economics
9:50
A Nordic update - market access outlook
Rasmus Jensen, Senior Director, Market Access , Camurus AB
10:30
Morning Coffee
11:00
The UK pricing and reimbursement landscape
David Watson, Director of Pricing and PPRS, Association of the British Pharmaceutical Industry (ABPI)
11:40
East meets West: The Turkish story on market access
Donald Macarthur, Adviser, Proceutica
12:20
Networking Lunch
13:20
An update from the US
Ken Walsh, Associate - Pricing and Market Access, Navigant
14:00
PANEL DISCUSSION: Innovative solutions: Improve quality and reduce costs
Simone Breitkopf, Head HEOR, Governmental and Public Affairs, Alcon
14:30
Afternoon Tea
15:00
Current trends in Health Technology Assessment (HTA) and value-related measures
Simone Breitkopf, Head HEOR, Governmental and Public Affairs, Alcon
15:40
Gene and cell therapies - focusing on expensive and process-intensive therapies
Panos Kefalas, Head of Health Economics and Market Access, Cell and Gene Therapy Catapult
16:20
Chairman’s Closing Remarks and Close of Day Two

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report